Grande L, Lacima G, Ros E, García-Valdecasas J C, Fuster J, Visa J, Pera C
Department of Surgery, Hospital Clinic i Provincial, University of Barcelona, Spain.
Dig Dis Sci. 1992 Apr;37(4):583-8. doi: 10.1007/BF01307583.
The acute effects of oral metoclopramide (40 mg/day) and domperidone (80 mg/day) on esophageal motor activity and acid reflux were assessed in a randomized, double-blind, placebo-controlled study in 20 patients with erosive reflux esophagitis. Esophageal motor function was assessed by standard manometry with wet swallows, and reflux events were evaluated by ambulatory 24-hr pH-monitoring. Both drugs caused a significant (P less than 0.05) increase in lower esophageal sphincter pressure lasting at least 120 min. However, neither esophageal body motility, duration of esophageal exposure to acid, nor esophageal clearance were effected by drug administration in comparison to placebo. Side effects were reported in two patients who received metoclopramide, while no adverse effects occurred after domperidone intake. In conclusion, the so-called motility agents metoclopramide and domperidone have few acute effects on esophageal motility in patients with erosive reflux esophagitis.
在一项针对20例糜烂性反流性食管炎患者的随机、双盲、安慰剂对照研究中，评估了口服胃复安（40毫克/天）和多潘立酮（80毫克/天）对食管运动活性和胃酸反流的急性影响。通过标准测压法和湿吞咽评估食管运动功能，通过动态24小时pH监测评估反流事件。两种药物均使食管下括约肌压力显著（P<0.05）升高，且持续至少120分钟。然而，与安慰剂相比，药物给药对食管体部运动、食管暴露于酸的持续时间或食管清除均无影响。接受胃复安治疗的两名患者报告了副作用，而服用多潘立酮后未出现不良反应。总之，所谓的促动力剂胃复安和多潘立酮对糜烂性反流性食管炎患者的食管运动几乎没有急性影响。
